FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience

 
• By Sarah Karlin-Smith

A long-time FDA veteran who remains largely unknown to the generics industry, Kathleen Uhl replaces CDER Director Janet Woodcock as acting director of the Office of Generic Drugs effective March 19 following Gregory Geba’s March 15 departure from the generic office’s top post.

Kathleen Uhl, an FDA veteran but relative newcomer to generic drugs, has become the third director for the Office of Generic Drugs in as many workdays.

Uhl’s March 19 appointment as acting director comes less than a week after FDA said CDER Director Janet Woodcock would assume the acting director role while FDA initiates a nationwide search for a permanent director to replace Gregory Geba who departed March 15 after only eight months on the

More from United States

More from North America